The initiation of coverage by a major financial institution like Goldman Sachs generally attracts investor attention. However, the Neutral rating suggests that Goldman Sachs views Rocket Pharmaceuticals as fairly valued at its current price, implying limited short-term price movement. The price target of $39 provides a reference point for investors but does not suggest significant upside or downside, hence the neutral impact score.